multiple myeloma case study progression

Multiple myeloma consistently is preceded by precursor states, which often are diagnosed incidentally in the laboratory. This case report illustrates the clinical dilemma of progression from precursor to full malignancy. The article also discusses future directions in management and research focusing on myelomagenesis.

Two independent studies showed that multiple myeloma consis - tently is preceded by MGUS (Landgren et al., 2009; Weiss, Abadie, Verma, Howard, & Kuehl, 2009). Smoldering multiple my - eloma is another asymptomatic precursor to multiple myeloma with a substantially higher annual risk of progression. Smol - dering multiple myeloma is de ned by a

The primary end point of the study was progression to multiple myeloma or other plasma-cell or lymphoid disorders among patients with MGUS in a cohort of 1384 patients.

A Case Study Progression to Multiple Myeloma. CJON 2010, 14 (4), 419-422. DOI: 10.1188/10.CJON.419-422. Multiple myeloma consistently is preceded by precursor states, which often are diagnosed incidentally in the laboratory. This case report illustrates the clinical dilemma of progression from precursor to full malignancy.

DISEASE OVERVIEW. Multiple myeloma accounts for 1% of all cancers and approximately 10% of all hematologic malignancies. 1,2 Each year over 32,000 new cases are diagnosed in the United States, and almost 13,000 patients die of the disease. 3 The annual age-adjusted incidence in the United States has remained stable for decades at approximately 4 per 100,000. 4 Multiple myeloma is slightly more ...

The phase 3 DETERMINATION trial showed the superiority of ASCT-based first-line therapy with respect to progression-free survival among eligible patients with newly diagnosed myeloma, findings ...

Case 58408 exemplified the ... J. S. et al. Molecular signatures of multiple myeloma progression through ... and professionals who have contributed to this study and the Multiple Myeloma Research ...

Abstract. The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to ...

Purpose Randomized multiple myeloma (MM) studies show improved response rates and better progression-free survival for newer therapies. However, a less pronounced effect has been found for overall ...

Note: The true teaching point of this case study is that t(11;14) exists in mantle cell lymphoma and multiple myeloma, and it may identify a possibly good prognostic group. References. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.

A case report illustrates the clinical dilemma of progression from precursor to full malignancy and discusses future directions in management and research focusing on myelomagenesis. Multiple myeloma consistently is preceded by precursor states, which often are diagnosed incidentally in the laboratory. This case report illustrates the clinical dilemma of progression from precursor to full ...

Biomarkers reliably predicting progression to multiple myeloma (MM) are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1α), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), fractalkine, and transforming growth factor-alpha (TGF-α).

Repeat q35 days ×9 cycles. Lenalidomide 15 mg PO days 1-21 (or last tolerated dose as of cycle 9) Bortezomib 1.3 mg/m2 SC days 1, 15, 22 (or last tolerated dose as of cycle 9) ORR = overall response rate; OS = overall survival; PFS = progression‐free survival; PO = by mouth; q = every; RVd = lenalidomide bortezomib dexamethasone; SC ...

Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor 5-8 and immunomodulatory 9-11 mechanisms of action. Daratumumab has been approved for use in combination with ...

study is expected to provide more data on the long-term effects of consolidation and maintenance. Keywords: MM, multiple myeloma, induction, daratumumab, quadruplet, real world MM-145 Active Multiple Myeloma in β-Thalassemia: A Case Report Mona Taalab MD, PhD1, Marwa Zaki MD, PhD2, Raghda Khalifa MD1

A new study suggests that a person's risk of progressing from a benign condition called monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, a type of blood cancer, can change over time.. On average, about 1% of people with MGUS go on to develop multiple myeloma each year. Doctors typically estimate a person's risk of progressing soon after MGUS is diagnosed ...

The incorporation of novel agents (NA) for multiple myeloma (MM) has improved the response rates (RR), overall survival (OS), and progression free survival (PFS) when compared to conventional agents (CA). Unfortunately, relapse is inevitable and few studies focus on patterns of relapse, especially in non-transplant patients (pts).

Cancer progression: Multiple myeloma can be asymptomatic and progress slowly, ... this is not always the case. When multiple myeloma comes back, ... In a 2021 study, researchers evaluated 12,987 ...

This dimension of the case underscores a couple of things. In a patient with standard-risk myeloma, we typically expect, based on some previous studies such as the STaMINA trial and the IFM 2009 trial, to see a progression-free survival with a package of induction, transplant, and lenalidomide maintenance of around 3 to 4 years, based on those ...

Joshua Richter, MD: Absolutely. This is a case of a 65-year-old [woman] with IgA [immunoglobulin A] lambda plus lambda multiple myeloma. She was originally diagnosed in 2011 with Durie-Salmon stage IIIA disease, a normal karyotype. She began her induction therapy with bortezomib and dexamethasone, which was later enhanced to VCD [bortezomib ...

Many studies have documented racial, socioeconomic, geographic, and other disparities for United States (US) patients with multiple myeloma pertaining to diagnosis and frontline management. In ...

Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma. 14-16 In this study, progression-free survival ...

Although multiple myeloma is an incurable disease, the past decade has witnessed significant improvement in patient outcomes. This was brought about by the development of T-cell redirection therapies such as chimeric antigen receptor (CAR) T-cells, which can leverage the natural ability of the immune system to fight myeloma cells.

Smoldering multiple myeloma is another asymptomatic precursor to multiple myeloma with a substantially higher annual risk of progression. Smoldering multiple myeloma is defined by a monoclonal-protein concentration of 3 g/dl or higher or 10% or higher bone marrow plasma cells in the absence of end-organ damage ( International Myeloma Working ...

Autologous hematopoietic cell transplant (HCT) is an effective treatment for patients with multiple myeloma (MM), especially for individuals who are medically fit and demonstrate disease response to induction therapy. 1,2 In fact, MM is the most common indication for autologous HCT, with more than 7000 patients undergoing transplant annually in ...

In this study, we identify ubiquitin-specific protease 2 (USP2) as a novel deubiquitinating enzyme of KRAS in multiple myeloma (MM). Specifically, we demonstrate that gambogic acid (GA) forms a covalent bond with the Cysteine 284 residue of USP2 through an allosteric pocket, inhibiting its deubiquitinating activity. ... case study using proline ...

Relapsed and/or refractory multiple myeloma patients previously treated with ≥2 lines of therapy were enrolled on a phase 1b study to assess safety and recommend a phase two dose of vactosertib ...

Subsequent studies also found that the CARG tool may predict toxicities in lymphoma and multiple myeloma. 33 The CARG breast cancer model focuses on patients with localized breast cancer receiving adjuvant or neoadjuvant regimens. The CRASH model applies to older patients with both solid tumor and hematologic malignancies.

The first Phase I clinical trial indicated that 9a is well tolerated in healthy subjects up to the maximum 600 mg single dose regimen or multiple doses of 300 mg/day. 308 Another Phase I clinical trial executed in early-stage HD patients indicated that 9a is safe at 10 and 100 mg/day and could provide clinical, cognitive, and neuropsychiatric ...

Targeted protein degradation in recent decades has emerged as a revolutionary therapeutic strategy in oncology. Prototypical immunomodulatory imide drugs (IMiDs) including thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of various hematological cancers such as multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B cell lymphoma (DLBCL) [1,2,3].